



MAX-PLANCK-GESELLSCHAFT



Universität
Augsburg
University



TECHNISCHE
UNIVERSITÄT
MÜNCHEN

THE GEORGE
WASHINGTON
UNIVERSITY
LAW SCHOOL
WASHINGTON DC

MIPLC Studies

Edited by

Prof. Dr. Christoph Ann, LL.M. (Duke Univ.)
Technische Universität München

Prof. Robert Brauneis
The George Washington University Law School

Prof. Dr. Josef Drexl, LL.M. (Berkeley)
Max Planck Institute for Intellectual Property and
Competition Law

Prof. Dr. Thomas M.J. Möllers
University of Augsburg

Prof. Dr. Dres. h.c. Joseph Straus,
Max Planck Institute for Intellectual Property and
Competition Law

Volume 12

Hyewon Ahn

Patentability of
Chemical Selection Inventions:
The Olanzapine and Escitalopram Decisions



Nomos

MIPLC

Munich
**Intellectual
Property**
Law Center

Augsburg
München
Washington DC

Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Daten sind im Internet über <http://dnb.d-nb.de> abrufbar.

Die Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.d-nb.de>.

a.t.: Munich, Univ., Diss., 2010

ISBN 978-3-8329-6524-2

1. Edition 2011

© Nomos Verlagsgesellschaft, Baden-Baden 2011. Printed in Germany.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use a fee is payable to »Verwertungsgesellschaft Wort«, Munich.

Acknowledgement

It is with utmost gratitude that I heartily appreciate the advice, encouragement, and support of my supervisor, Prof. Dr. Heinz Goddar, who enabled me to develop the research and to finish this thesis. I would like to especially thank our Program Director, Dr. Nari Lee who was always standing by me, for her guidance, helps, insights on my thesis. I am also indebted to my tutor, Dr. Christof Karl who made available his support and guidance in a number of ways from the beginning to the last of my thesis. Special thanks goes to my office mate, Chen Xi, who was always willing to help and to give suggestions. It would have been a lonely office without her. I also benefitted a lot from conversations with Ilho Lee, Heeun Kim, and Max Wallot, whom I thank for being always there.

Lastly, I would like to thank my parents and my sister. They were always supporting and encouraging me with their best wishes from home.

Table of Contents

I. Introduction	11
II. Background	17
A. Markush type claim	17
B. Enantiomers and Related Patents	17
III. Jurisprudence on the patentability requirements for selection inventions	21
A. Facts of the Cases	21
1. Facts in Olanzapine	21
2. Facts in Escitalopram	21
B. Novelty Requirement	22
1. From the German Perspective: “Parting from Fluoran”	22
a) Markush Claim – Olanzapine Decision	23
(1) Federal Patent Court Decision	23
(2) Federal Court of Justice Decision	24
b) Enantiomer Invention – Escitalopram Decision	26
(1) Federal Patent Court Decision	26
(2) Federal Court of Justice Decision	26
2. From the U.S. Perspective	27
a) Markush Claim – Olanzapine Decision	27
b) Enantiomer Invention – Escitalopram Decision	28
3. From the UK Perspective: “Parting from IG Rule”	28
a) Markush Claim – Olanzapine Decision	29
(1) Patent Court Decision	29
(2) Court of Appeal Decision	29
b) Enantiomer Invention – Escitalopram Decision	30
4. Summary	31
C. Nonobviousness Requirement	31
1. From the German Perspective	31
a) Markush Claim – Olanzapine Decision	31
b) Enantiomer Invention – Escitalopram Decision	33
2. From the U.S. Perspective	33
a) Markush Claim – Olanzapine Decision	33
b) Enantiomer Invention – Escitalopram Decision	34

3.	From the UK Perspective	35
a)	Markush Claim – Olanzapine Decision	35
	(1) Patent Court Decision	35
	(2) Court of Appeal Decision	36
b)	Enantiomer Invention – Escitalopram Decision	36
	(1) Court of Appeal Decision	36
	(2) The House of Lords Decision	37
4.	Summary	37
D.	Summary and Conclusion	38
IV.	Discussion	39
A.	Anticipation	39
1.	Relativity of Novelty	39
2.	Enablement as a Requirement for Anticipation	42
3.	Implications of Enablement Requirement in Anticipation	44
a)	The Test of Anticipation: Precedent Test of Obviousness?	44
b)	A Possible Ground for Challenging the Basic Patent	45
c)	Other Implications of the Rules for Disclosure in the Olanzapine Case	46
4.	Conclusion	47
B.	Obviousness	48
1.	Prima Facie Obviousness	48
a)	Size of the Genus	48
b)	Structural Similarity	49
c)	Reasonable Expectation of Success	50
2.	Overcoming Obviousness	51
a)	Teach away	51
b)	Unexpected Results	51
c)	Other Secondary Considerations	52
3.	Considerations	52
a)	Person Skilled in the Art in the Olanzapine Decision	52
b)	Reasonable Expectation of Success: Escitalopram Decision	53
4.	Conclusion	54
C.	Impact of Lowering the Bar for the Patentability of Selection Inventions	54
1.	Easier Extension of Exclusive Right: “Evergreening” or “Life- Cycle Management”	55
2.	More Limitations to Exploiting Selection Patents	55
a)	Scope of a Selection Invention over a Basic Patent	55

b) Possible Solutions	57
(1) Reverse Doctrine of Equivalence	57
(2) Patent Act Consideration – Compulsory License	58
(3) Competition Law Consideration – the Orange Book Standard Decision	60
c) Conclusion	61
D. Different view in other jurisdictions	61
1. Selection Inventions in Korea	61
a) Clopidogrel Decision	61
b) Atorvastatin Decision	62
2. Selection Inventions in Japan	63
3. Summary and Conclusion	64
V. Conclusion	65
Abstract	67
List of Works Cited	69

